Literature DB >> 20963725

Molecular mechanisms of RIP, an effective inhibitor of chronic infections.

Florencia Lopez-Leban1, Madanahally Divakar Kiran, Randall Wolcott, Naomi Balaban.   

Abstract

Non-healing bacterial infections are often associated with the formation of a biofilm, where bacteria are more resistant to conventional treatment modalities and to host immune responses. We show here that RNAIII inhibiting peptide (RIP), a linear heptapeptide, is very effective in treating severe polymicrobial infections, including drug-resistant staphylococci like MRSA. By functional genomics studies (microarray analysis) on Staphylococcus aureus, we show here that RIP downregulates the expression of genes involved in biofilm formation and toxin production, and upregulates genes involved in stress response. This pattern of gene regulation may explain why RIP has been so effective in treating severe infections and hopefully through the addition of RIP to existing protocols, a new way of tackling chronic persistent infections will be established.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20963725     DOI: 10.1177/039139881003300904

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN: 0391-3988            Impact factor:   1.595


  13 in total

1.  The root-specific NtR12 promoter-based expression of RIP increased the resistance against bacterial wilt disease in tobacco.

Authors:  Tiecheng Cai; Hua Chen; Liming Yan; Chong Zhang; Ye Deng; Shengxin Wu; Qiang Yang; Ronglong Pan; Ali Raza; Shunhui Chen; Weijian Zhuang
Journal:  Mol Biol Rep       Date:  2022-09-12       Impact factor: 2.742

2.  Posttranscriptional regulation of oral bacterial adaptive responses.

Authors:  Justin Merritt; Zhiyun Chen; Nan Liu; Jens Kreth
Journal:  Curr Oral Health Rep       Date:  2014-03-01

3.  Impact of agr dysfunction on virulence profiles and infections associated with a novel methicillin-resistant Staphylococcus aureus (MRSA) variant of the lineage ST1-SCCmec IV.

Authors:  Fabienne Antunes Ferreira; Raquel Rodrigues Souza; Bruno de Sousa Moraes; Ana Maria de Amorim Ferreira; Marco Antônio Américo; Sérgio Eduardo Longo Fracalanzza; José Nelson Dos Santos Silva Couceiro; Agnes Marie Sá Figueiredo
Journal:  BMC Microbiol       Date:  2013-04-27       Impact factor: 3.605

4.  Susceptibility of Pseudomonas aeruginosa Biofilm to Alpha-Helical Peptides: D-enantiomer of LL-37.

Authors:  Scott N Dean; Barney M Bishop; Monique L van Hoek
Journal:  Front Microbiol       Date:  2011-07-04       Impact factor: 5.640

5.  Natural and synthetic cathelicidin peptides with anti-microbial and anti-biofilm activity against Staphylococcus aureus.

Authors:  Scott N Dean; Barney M Bishop; Monique L van Hoek
Journal:  BMC Microbiol       Date:  2011-05-23       Impact factor: 3.605

Review 6.  Antibacterial surface treatment for orthopaedic implants.

Authors:  Jiri Gallo; Martin Holinka; Calin S Moucha
Journal:  Int J Mol Sci       Date:  2014-08-11       Impact factor: 5.923

Review 7.  Ureteral stent technology: Drug-eluting stents and stent coatings.

Authors:  Luo Yang; Samantha Whiteside; Peter A Cadieux; John D Denstedt
Journal:  Asian J Urol       Date:  2015-09-21

8.  The Human Cathelicidin Antimicrobial Peptide LL-37 as a Potential Treatment for Polymicrobial Infected Wounds.

Authors:  Allen J Duplantier; Monique L van Hoek
Journal:  Front Immunol       Date:  2013-07-03       Impact factor: 7.561

Review 9.  Deciphering mechanisms of staphylococcal biofilm evasion of host immunity.

Authors:  Mark L Hanke; Tammy Kielian
Journal:  Front Cell Infect Microbiol       Date:  2012-05-08       Impact factor: 5.293

10.  First evidence of sternal wound biofilm following cardiac surgery.

Authors:  Haytham Elgharably; Ethan Mann; Hamdy Awad; Kasturi Ganesh; Piya Das Ghatak; Gayle Gordillo; Chittoor B Sai-Sudhakar; Sashwati Roy; Daniel J Wozniak; Chandan K Sen
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.